Compare ASTRAZENECA PHARMA with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA LUPIN ASTRAZENECA PHARMA/
LUPIN
 
P/E (TTM) x 110.9 -19.0 - View Chart
P/BV x 15.0 2.1 714.2% View Chart
Dividend Yield % 0.1 1.0 7.1%  

Financials

 ASTRAZENECA PHARMA   LUPIN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-21
LUPIN
Mar-21
ASTRAZENECA PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs4,9701,122 443.0%   
Low Rs2,348576 407.9%   
Sales per share (Unadj.) Rs325.4334.2 97.4%  
Earnings per share (Unadj.) Rs37.327.0 138.0%  
Cash flow per share (Unadj.) Rs45.446.6 97.4%  
Dividends per share (Unadj.) Rs2.006.50 30.8%  
Avg Dividend yield %0.10.8 7.1%  
Book value per share (Unadj.) Rs181.8300.1 60.6%  
Shares outstanding (eoy) m25.00453.68 5.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x11.22.5 442.8%   
Avg P/E ratio x98.031.4 312.3%  
P/CF ratio (eoy) x80.618.2 442.7%  
Price / Book Value ratio x20.12.8 711.4%  
Dividend payout %5.424.0 22.3%   
Avg Mkt Cap Rs m91,478385,072 23.8%   
No. of employees `000NANA-   
Total wages/salary Rs m2,19528,259 7.8%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m8,136151,630 5.4%  
Other income Rs m1281,363 9.4%   
Total revenues Rs m8,264152,993 5.4%   
Gross profit Rs m1,35525,669 5.3%  
Depreciation Rs m2018,874 2.3%   
Interest Rs m111,406 0.8%   
Profit before tax Rs m1,27116,751 7.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3384,485 7.5%   
Profit after tax Rs m93312,266 7.6%  
Gross profit margin %16.716.9 98.4%  
Effective tax rate %26.626.8 99.3%   
Net profit margin %11.58.1 141.8%  
BALANCE SHEET DATA
Current assets Rs m6,887139,864 4.9%   
Current liabilities Rs m3,73484,361 4.4%   
Net working cap to sales %38.836.6 105.9%  
Current ratio x1.81.7 111.2%  
Inventory Days Days4569 65.2%  
Debtors Days Days38108 35.5%  
Net fixed assets Rs m1,85594,439 2.0%   
Share capital Rs m50907 5.5%   
"Free" reserves Rs m4,496135,229 3.3%   
Net worth Rs m4,546136,136 3.3%   
Long term debt Rs m0161 0.0%   
Total assets Rs m8,742234,302 3.7%  
Interest coverage x117.612.9 910.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.6 143.8%   
Return on assets %10.85.8 185.0%  
Return on equity %20.59.0 227.8%  
Return on capital %28.213.3 211.7%  
Exports to sales %00-   
Imports to sales %29.30-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m2,382NA-   
Fx inflow Rs m31851,027 0.6%   
Fx outflow Rs m2,38221,081 11.3%   
Net fx Rs m-2,06429,946 -6.9%   
CASH FLOW
From Operations Rs m1,04818,218 5.8%  
From Investments Rs m1,730-12,396 -14.0%  
From Financial Activity Rs m-90-18,853 0.5%  
Net Cashflow Rs m2,688-13,031 -20.6%  

Share Holding

Indian Promoters % 0.0 46.5 -  
Foreign collaborators % 75.0 0.3 26,785.7%  
Indian inst/Mut Fund % 3.6 41.9 8.5%  
FIIs % 2.4 14.7 16.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.0 53.2 47.0%  
Shareholders   57,760 378,547 15.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    

Yellow Ad

Advertisement

A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more



Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling(Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 24, 2022 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS